Towards finite oral antiviral treatment for chronic hepatitis B

Affiliations

¹ Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
² Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: hlychan@cuhk.edu.hk.

Comment

Grace Lai-Hung Wong et al. Lancet Gastroenterol Hepatol. 2019 Apr.

. 2019 Apr;4(4):260-262.

doi: 10.1016/S2468-1253(19)30045-7. Epub 2019 Feb 20.

¹ Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
² Institute of Digestive Disease, Department of Medicine and Therapeutics, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China. Electronic address: hlychan@cuhk.edu.hk.

No abstract available

Comment on

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.
Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Buti M, et al. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20. Lancet Gastroenterol Hepatol. 2019. PMID: 30795958 Clinical Trial.